Hospitals are more likely than medical groups and physician management companies to acquire unprofitable physician practices, according to a recent survey released in "The 1997-1998 Physician Practice Acquisition Resource Book."
Hospitals are more likely than medical groups and physician management companies to acquire unprofitable physician practices, according to a recent survey released in "The 1997-1998 Physician Practice Acquisition Resource Book."
The survey, conducted by The Center for Health Care Industry Performance Studies, draws its conclusions from 460 physician practice acquisitions made between 1994 and 1996. It represents more than 1,200 physicians from numerous specialties.
According to William Cleverly, Ph.D., who co-wrote the book with Patrick Knott and Carson Dye, there are several reasons why hospitals may acquire unprofitable physician practices.
"First, hospitals tend to pay higher salaries to employed physicians than other firms do, and second, hospital management may believe there are substantial opportunities to raise practice revenues or decrease costs to make the practices more profitable," Cleverly said.
But a third reason, according to the authors, may be the substantial opportunities for additional referral revenue for the hospital. "This strategy is, of course, illegal," Cleverly said.
The survey also uncovered a misperception about physician practice acquisitions. While it is generally assumed that tangible assets - accounts receivable, property and equipment - make up only a small percentage of a total purchase price, survey results indicated that the percentage is actually much higher than previously believed. PR
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.